Low‐dose venetoclax, bortezomib, inotuzumab, rituximab, and dexamethasone (LoVe‐BIRD) in a child with relapsed/refractory B‐cell acute lymphoblastic leukemia with TP53 mutation
Pediatric Blood & Cancer · 2024
DOI: 10.1002/pbc.31152 ↗Kurz gefasst
Leserbrief in der Zeitschrift Pediatric Blood & Cancer, 2024. Verfasst von Vivek Mohan und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology and Bone Marrow Transplant, Paras Health, Gurugram, Haryana, India. Hauptthemen laut MEDLINE: Bridged Bicyclo Compounds, Heterocyclic, Antineoplastic Combined Chemotherapy Protocols, Dexamethasone, Bortezomib. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 18 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Hematology and Bone Marrow Transplant, Paras Health, Gurugram, Haryana, India.
ORCID-Profile: Vivek Mohan, Rahul Naithani
Zitieren
APA
Mohan, V., Jain, S., & Naithani, R. (2024). Low‐dose venetoclax, bortezomib, inotuzumab, rituximab, and dexamethasone (LoVe‐BIRD) in a child with relapsed/refractory B‐cell acute lymphoblastic leukemia with TP53 mutation. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.31152
Vancouver
Mohan V, Jain S, Naithani R. Low‐dose venetoclax, bortezomib, inotuzumab, rituximab, and dexamethasone (LoVe‐BIRD) in a child with relapsed/refractory B‐cell acute lymphoblastic leukemia with TP53 mutation. Pediatric Blood & Cancer. 2024. doi:10.1002/pbc.31152
BibTeX
@article{Mohan2024,
author = {Mohan, Vivek and Jain, Sachin and Naithani, Rahul},
title = {Low‐dose venetoclax, bortezomib, inotuzumab, rituximab, and dexamethasone (LoVe‐BIRD) in a child with relapsed/refractory B‐cell acute lymphoblastic leukemia with TP53 mutation},
journal = {Pediatric Blood & Cancer},
year = {2024},
doi = {10.1002/pbc.31152}
}
EUVIMED